Restless Legs Syndrome in Patients With Chronic Kidney Disease

Seminars in Nephrology

Volumn 35, Issue 4, 2015, Pages 347-358

  Novak, Marta ^a,b   Winkelman, John W ^c   Unruh, Mark ^d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Dialysis; Kidney transplantation; Quality of life; Restless legs syndrome; Sleep

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; IRON DEXTRAN; LEVODOPA; NARCOTIC ANALGESIC AGENT; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DIALYSIS SCHEDULE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; HUMAN; IRON METABOLISM DISORDER; IRON THERAPY; KINESIOTHERAPY; MORBIDITY; NONHUMAN; OPEN STUDY; PATHOPHYSIOLOGY; PATIENT RISK; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SYMPTOM; COMPLICATION; KIDNEY FAILURE, CHRONIC; RISK FACTOR;

HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RENAL DIALYSIS; RESTLESS LEGS SYNDROME; RISK FACTORS;

EID: 84940907956     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.06.006     Document Type: Review

References (99)

1. Trenkwalder C., Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010, 6:337-346.
2. Earley C.J., Allen R.P., Hening W. Restless legs syndrome and periodic leg movements in sleep. Handb Clin Neurol 2011, 99:913-948.
3. Winkelman J.W., Finn L., Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006, 7:545-552.
4. Fuhs A., Bentama D., Antkowiak R., Mathis J., Trenkwalder C., Berger K. Effects of short- and long-term variations in RLS severity on perceived health status - the COR-study. PLoS One 2014, 9:e94821.
5. International Restless Legs Syndrome Study Group. 2012 revised IRLSSG diagnostic criteria for RLS. [cited 2013 Aug 15]. Available from: . http://irlssg.org/diagnostic-criteria/.
6. Araujo S.M., de Bruin V.M., Nepomuceno L.A., Maximo M.L., Daher Ede F., Correia Ferrer D.P., et al. Restless legs syndrome in end-stage renal disease: clinical characteristics and associated comorbidities. Sleep Med 2010, 11:785-790.
7. Gigli G.L., Adorati M., Dolso P., Piani A., Valente M., Brotini S., et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004, 5:309-315.
8. Lin C.H., Wu V.C., Li W.Y., Sy H.N., Wu S.L., Chang C.C., et al. Restless legs syndrome in end-stage renal disease: a multicenter study in Taiwan. Eur J Neurol 2013, 20:1025-1031.
9. Takaki J., Nishi T., Nangaku M., Shimoyama H., Inada T., Matsuyama N., et al. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis 2003, 41:833-839.
10. Allen R.P., Bharmal M., Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011, 26:114-120.
11. Allen R.P., Walters A.S., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292.
12. Szentkiralyi A., Völzke H., Hoffmann W., Trenkwalder C., Berger K. Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies. Neurology 2014, 82:2026-2033.
13. Merlino G., Lorenzut S., Gigli G.L., Romano G., Montanaro D., Moro A., et al. A case-control study on restless legs syndrome in nondialyzed patients with chronic renal failure. Mov Disord 2010, 25:1019-1025.
14. Molnar M.Z., Novak M., Ambrus C., Szeifert L., Kovacs A., Pap J., et al. Restless legs syndrome in patients after renal transplantation. Am J Kidney Dis 2005, 45:388-396.
15. Molnar M.Z., Szentkiralyi A., Lindner A., Czira M.E., Szeifert L., Kovacs A.Z., et al. Restless legs syndrome and mortality in kidney transplant recipients. Am J Kidney Dis 2007, 50:813-820.
16. Winkelman J.W., Chertow G.M., Lazarus J.M. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996, 28:372-378.
17. Kutner N.G., Zhang R., Bliwise D.L. Restless legs syndrome is underdiagnosed in the US Renal Data System. QJM 2013, 106:487.
18. Benes H., Walters A.S., Allen R.P., Hening W.A., Kohnen R. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord 2007, 22(Suppl 18):S401-S408.
19. Molnar M.Z., Novak M., Mucsi I. Management of restless legs syndrome in patients on dialysis. Drugs 2006, 66:607-624.
20. Winkelmann J., Wetter T.C., Collado-Seidel V., Gasser T., Dichgans M., Yassouridis A., et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000, 23:597-602.
21. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J. , the participants in the Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health in collaboration with members of the International Restless Legs Syndrome Study Group Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
22. Rye D.B., Trotti L.M. Restless legs syndrome and periodic leg movements of sleep. Neurol Clin 2012, 30:1137-1166.
23. Pennestri M.H., Whittom S., Adam B., Petit D., Carrier J., Montplaisir J. PLMS and PLMW in healthy subjects as a function of age: prevalence and interval distribution. Sleep 2006, 29:1183-1187.
24. Enomoto M., Inoue Y., Namba K., Munezawa T., Matsuura M. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients. Mov Disord 2008, 23:811-816. quiz 926.
25. Parker K.P., Bliwise D.L., Bailey J.L., Rye D.B. Polysomnographic measures of nocturnal sleep in patients on chronic, intermittent daytime haemodialysis vs those with chronic kidney disease. Nephrol Dial Transplant 2005, 20:1422-1428.
26. Winkelman J.W., Allen R.P., Tenzer P., Hening W. Restless legs syndrome: nonpharmacologic and pharmacologic treatments. Geriatrics 2007, 62:13-16.
27. Allen R.P. Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. Am J Med 2007, 120:S13-S21.
28. Earley C.J., Allen R.P., Beard J.L., Connor J.R. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 2000, 62:623-628.
29. Collado-Seidel V., Kohnen R., Samtleben W., Hillebrand G.F., Oertel W.H., Trenkwalder C. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998, 31:324-328.
30. Unruh M.L., Levey A.S., D'Ambrosio C., Fink N.E., Powe N.R., Meyer K.B. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis 2004, 43:900-909.
31. Schormair B., Plag J., Kaffe M., Gross N., Czamara D., Samtleben W., et al. MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease. J Med Genet 2011, 48:462-466.
32. Molnar M.Z., Novak M., Szeifert L., Ambrus C., Keszei A., Koczy A., et al. Restless legs syndrome, insomnia, and quality of life after renal transplantation. J Psychosom Res 2007, 63:591-597.
33. Winkelmann J., Stautner A., Samtleben W., Trenkwalder C. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord 2002, 17:1072-1076.
34. Cirignotta F., Mondini S., Santoro A., Ferrari G., Gerardi R., Buzzi G. Reliability of a questionnaire screening restless legs syndrome in patients on chronic dialysis. Am J Kidney Dis 2002, 40:302-306.
35. Becker P.M., Novak M. Diagnosis, comorbidities, and management of restless legs syndrome. Curr Med Res Opin 2014, 30:1441-1460.
36. De Santo R.M., Cesare C.M., Bartiromo M., Cirillo M. High prevalence of sleep disorders at the time of CKD diagnosis. J Ren Nutr 2008, 18:104-106.
37. Iliescu E.A., Yeates K.E., Holland D.C. Quality of sleep in patients with chronic kidney disease. Nephrol Dial Transplant 2004, 19:95-99.
38. Sabbatini M., Pisani A., Crispo A., Ragosta A., Gallo R., Pota A., et al. Sleep quality in patients with chronic renal failure: a 3-year longitudinal study. Sleep Med 2008, 9:240-246.
39. Araujo S.M., Bruin V.M., Daher E.F., Medeiros C.A., Almeida G.H., Bruin P.F. Quality of sleep and day-time sleepiness in chronic hemodialysis: a study of 400 patients. Scand J Urol Nephrol 2011, 45:359-364.
40. Mucsi I., Molnar M.Z., Ambrus C., Szeifert L., Kovacs A.Z., Zoller R., et al. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant 2005, 20:571-577.
41. Molnar M.Z., Novak M., Mucsi I. Sleep disorders and quality of life in renal transplant recipients. Int Urol Nephrol 2009, 41:373-382.
42. (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3:1-150. Kidney Disease: Improving Global Outcomes.
43. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
44. Batool-Anwar S., Malhotra A., Forman J., Winkelman J., Li Y., Gao X. Restless legs syndrome and hypertension in middle-aged women. Hypertension 2011, 58:791-796.
45. Koo B.B., Blackwell T., Ancoli-Israel S., Stone K.L., Stefanick M.L., Redline S. for the Osteoporotic Fractures in Men (MrOS) Study Group. Association of incident cardiovascular disease with periodic limb movements during sleep in older men: outcomes of sleep disorders in older men (MrOS) study. Circulation 2011, 124:1223-1231.
46. Li Y., Walters A.S., Chiuve S.E., Rimm E.B., Winkelman J.W., Gao X. Prospective study of restless legs syndrome and coronary heart disease among women. Circulation 2012, 126:1689-1694.
47. Winkelman J.W., Shahar E., Sharief I., Gottlieb D.J. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008, 70:35-42.
48. Lindner A., Fornadi K., Lazar A.S., Czira M.E., Dunai A., Zoller R., et al. Periodic limb movements in sleep are associated with stroke and cardiovascular risk factors in patients with renal failure. J Sleep Res 2012, 21:297-307.
49. Li Y., Wang W., Winkelman J.W., Malhotra A., Ma J., Gao X. Prospective study of restless legs syndrome and mortality among men. Neurology 2013, 81:52-59.
50. La Manna G., Pizza F., Persici E., Baraldi O., Comai G., Cappuccilli M.L., et al. Restless legs syndrome enhances cardiovascular risk and mortality in patients with end-stage kidney disease undergoing long-term haemodialysis treatment. Nephrol Dial Transplant 2011, 26:1976-1983.
51. Giannaki C.D., Zigoulis P., Karatzaferi C., Hadjigeorgiou G.M., George K.P., Gourgoulianis K., et al. Periodic limb movements in sleep contribute to further cardiac structure abnormalities in hemodialysis patients with restless legs syndrome. J Clin Sleep Med 2013, 9:147-153.
52. Mucsi I., Molnar M.Z., Rethelyi J., Vamos E., Csepanyi G., Tompa G., et al. Sleep disorders and illness intrusiveness in patients on chronic dialysis. Nephrol Dial Transplant 2004, 19:1815-1822.
53. Novak M., Mendelssohn D., Shapiro C.M., Mucsi I. Diagnosis and management of sleep apnea syndrome and restless legs syndrome in dialysis patients. Semin Dial 2006, 19:210-216.
54. Szentkiralyi A., Molnar M.Z., Czira M.E., Deak G., Lindner A.V., Szeifert L., et al. Association between restless legs syndrome and depression in patients with chronic kidney disease. J Psychosom Res 2009, 67:173-180.
55. Giannaki C.D., Sakkas G.K., Karatzaferi C., Hadjigeorgiou G.M., Lavdas E., Liakopoulos V., et al. Evidence of increased muscle atrophy and impaired quality of life parameters in patients with uremic restless legs syndrome. PLoS One 2011, 6:e25180.
56. Miranda M., Kagi M., Fabres L., Aguilera L., Alvo M., Elgueta L., et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004, 62:831-832.
57. Giannaki C.D., Sakkas G.K., Hadjigeorgiou G.M., Karatzaferi C., Patramani G., Lavdas E., et al. Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome. ASAIO J 2010, 56:538-542.
58. Giannaki C.D., Sakkas G.K., Karatzaferi C., Hadjigeorgiou G.M., Lavdas E., Kyriakides T., et al. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrol 2013, 14:194.
59. Kutner N.G., Zhang R., Szczech L.A., Bliwise D.L. Restless legs syndrome reported by incident haemodialysis patients: is treatment time of day relevant?. Nephrology 2012, 17:783-784.
60. Silber M.H., Ehrenberg B.L., Allen R.P., Buchfuhrer M.J., Earley C.J., Hening W.A., et al. Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004, 79:916-922.
61. Jaber B.L., Schiller B., Burkart J.M., Daoui R., Kraus M.A., Lee Y., et al. on behalf of the FREEDOM Study Group. Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol 2011, 6:1049-1056.
62. Sloand J.A., Shelly M.A., Feigin A., Bernstein P., Monk R.D. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43:663-670.
63. 2δ ligands. Eur Neurol 2011, 66:18-29.
64. Cundy K.C., Branch R., Chernov-Rogan T., Dias T., Estrada T., Hold K., et al. XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004, 311:315-323.
65. Lal R., Sukbuntherng J., Luo W., Chen D., Blumenthal R., Ho J., et al. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Clin Ther 2012, 34:201-213.
66. Cundy K.C., Annamalai T., Bu L., De Vera J., Estrela J., Luo W., et al. XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004, 311:324-333.
67. Tan J., Derwa A., Sanu V., Rahman N. Woodrow G. Gabapentin in treatment of restless legs syndrome in peritoneal dialysis patients. Perit Dial Int 2006, 26:276-278.
68. Randinitis E.J., Posvar E.L., Alvey C.W., Sedman A.J., Cook J.A., Bockbrader H.N. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003, 43:277-283.
69. HORIZANT (gabapentin enacarbil) extended-release tablets for oral use: prescribing information. Santa Clara, CA: XenoPort, Inc.; 2013.
70. Garcia-Borreguero D., Kohnen R., Silber M.H., Winkelman J.W., Earley C.J., Högl B., et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013, 14:675-684.
71. Micozkadioglu H., Ozdemir F.N., Kut A., Sezer S., Saatci U., Haberal M. Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: an open-label study. Ren Fail 2004, 26:393-397.
72. Thorp M.L., Morris C.D., Bagby S.P. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001, 38:104-108.
73. Bogan R.K., Bornemann M.A., Kushida C.A., Trân P.V., Barrett R.W. and the XP060 Study Group. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc 2010, 85:512-521.
74. Kushida C.A., Walters A.S., Becker P., Thein S.G., Perkins A.T., Roth T., et al. and the XP021 Study Group. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009, 32:159-168.
75. Winkelman J.W., Bogan R.K., Schmidt M.H., Hudson J.D., DeRossett S.E., Hill-Zabala C.E. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2011, 26:2065-2072.
76. Allen R., Chen C., Soaita A., Wohlberg C., Knapp L., Peterson B.T., et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010, 11:512-519.
77. Garcia-Borreguero D., Larrosa O., Williams A.M., Albares J., Pascual M., Palacios J.C., et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010, 74:1897-1904.
78. Trenkwalder C., Beneš H., Grote L., García-Borreguero D., Högl B., Hopp M., et al. for the RELOXYN Study Group Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 2013, 12:1141-1150.
79. Walters A.S., Ondo W.G., Zhu W., Le W. Does the endogenous opiate system play a role in the restless legs syndrome? A pilot post-mortem study. J Neurol Sci 2009, 279:62-65.
80. Silver N., Allen R.P., Senerth J., Earley C.J. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011, 12:440-444.
81. Walters A.S., Winkelmann J., Trenkwalder C., Fry J.M., Kataria V., Wagner M., et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001, 16:1105-1109.
82. Dharia S.M., Brown L.K., Unruh M.L. Recognition and treatment of obstructive sleep apnea. Semin Dial 2013, 26:273-277.
83. Davison S.N. The prevalence and management of chronic pain in end-stage renal disease. J Palliat Med 2007, 10:1277-1287.
84. Kafkia T., Chamney M., Drinkwater A., Pegoraro M., Sedgewick J. Pain in chronic kidney disease: prevalence, cause and management. J Ren Care 2011, 37:114-122.
85. Pauli-Magnus C., Hofmann U., Mikus G., Kuhlmann U., Mettang T. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1999, 14:903-909.
86. Trenkwalder C., Hening W.A., Montagna P., Oertel W.H., Allen R.P., Walters A.S., et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008, 23:2267-2302.
87. Trenkwalder C., Stiasny K., Pollmächer T., Wetter T., Schwarz J., Kohnen R., et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995, 18:681-688.
88. Walker S.L., Fine A., Kryger M.H. L-DOPA/carbidopa for nocturnal movement disorders in uremia. Sleep 1996, 19:214-218.
89. García-Borreguero D., Williams A.M. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010, 14:339-346.
90. Steiger M., Jost W., Grandas F., Van Camp G. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm 2009, 116:179-191.
91. Ferini-Strambi L., Aarskog D., Partinen M., Chaudhuri K.R., Sohr M., Verri D., et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008, 9:874-881.
92. Hening W.A., Allen R.P., Ondo W.G., Walters A.S., Winkelman J.W., Becker P., et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010, 25:1675-1683.
93. Trenkwalder C., Benes H., Poewe W., Oertel W.H., Garcia-Borreguero D., de Weerd A.W., et al. for the SP790 Study Group. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008, 7:595-604.
94. Trenkwalder C., Garcia-Borreguero D., Montagna P., Lainey E., de Weerd A.W., Tidswell P., et al. on behalf of the TREAT RLS1 (Therapy with Ropinirole Efficacy and Tolerability in RLS1) Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004, 75:92-97.
95. Pellecchia M.T., Vitale C., Sabatini M., Longo K., Amboni M., Bonavita V., et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol 2004, 27:178-181.
96. Rauta V, Winkelman J, Dauvilliers Y, Partinen M, Benes H, Schroeder H, et al. Rotigotine in patients with Restless Legs Syndrome and end-stage renal disease requiring hemodialysis. J.Am.Soc.Nephrol. 2014;25(suppl.):320A.
97. MIRAPEX® (pramipexole dihydrochloride) tablets for oral administration. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2013.
98. REQUIP (ropinirole) tablets prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2014.
99. Cawello W., Ahrweiler S., Sulowicz W., Szymczakiewicz-Multanowska A., Braun M. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol 2012, 73:46-54.